Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | An insight into the Beat AML trial and the value of precision medicine

Amy Burd • 10 Dec 2022
ASH 2022
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin
Beat AML

Amy Burd, PhD, Leukemia & Lymphoma Society, New York, NY, briefly outlines the structure and aims of the Beat AML trial (NCT03013998), a precision medicine trial evaluating patients with newly diagnosed acute myeloid leukemia (AML). Following this, Dr Burd further highlights how precision medicine has improved the outcomes of patients with newly diagnosed disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amy Burd

0:56
Patient-reported outcomes explored in the Beat AML trial
Amy Burd • 10 Dec 2022
2:11
Beat AML Master Trial: novel precision medicine approach in AML
Amy Burd • 7 Dec 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals